$OBIO

Orchestra BioMed (OBIO) will host an R&D Day on November 12, 2026, to discuss AVIM Therapy and Virtue SAB. Key cardiologists will join to address unmet medical needs and upcoming milestones. The event will be held in NYC and via webcast. OBIO's products target hypertension and restenosis, with ongoing pivotal trials and FDA Breakthrough Device Designations.

Piper Sandler reiterated an Overweight rating and $12.00 price target for Orchestra BioMed (OBIO), citing progress in its AVIM therapy trial for hypertension. The firm projects global revenue of $37M by 2028 and $130M by 2030. OBIO stock is up 54% over the past year, trading at $5.69 with a $340M market cap. Other analysts also reiterated or upgraded their ratings, highlighting the trial's completion and potential growth.

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Orchestra BioMed (OBIO) after its hypertension trial completed enrollment. The stock trades at $5.95, with a 119.56% return over the past year. The BACKBEAT trial, conducted with Medtronic, aims to treat uncontrolled hypertension in pacemaker patients. Orchestra plans to submit results for regulatory review in 2027. BTIG also upgraded OBIO to Buy with a $10 target.

Analysts from B. Riley Securities and TD Cowen reiterated Buy ratings on Orchestra BioMed Holdings (OBIO), with price targets of $11.00 and $15.00, respectively. Regeneron (REGN) received a Buy rating from Goldman Sachs with a $972.00 price target. Both stocks have bullish analyst consensus.

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.

Orchestra BioMed (OBIO) completed its BACKBEAT trial with 330 patients, exceeding the 316-patient target. The global trial, conducted at 81 sites across 13 countries, aims to support Medtronic's regulatory applications. Primary endpoint data is expected to be submitted for presentation in Q2 2027, according to the company.

Orchestra BioMed (OBIO) announced it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial, with 330 patients randomized. The trial, conducted with Medtronic, evaluates AVIM Therapy for uncontrolled hypertension in pacemaker patients. Primary endpoint data is expected in Q2 2027, with potential regulatory submissions following.

Orchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Wealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.